London-based Sava completed an independent clinical study of 46 participants with type 1 and insulin-dependent type 2 diabetes. The study took place across sites in Oxford and Cambridge, UK. It demonstrated reliable glucose measurement using Sava’s proprietary microsensor technology over the 10-day wear period.
The company designed its multi-molecule biosensor to detecting biomarkers just beneath the skin in real-time. This proprietary technology powers the company’s first product, a pain-free CGM. The CGM streamlines molecular insights in real-time to a user’s phone.
Sava raised $19 million in its Series A funding round to support the technology in July 2025.
More about the study
The company said its study enabled a head-to-head comparison with a leading CGM. Each participant simultaneously wore a Sava microsensor and the undisclosed comparator CGM, benchmarking both against a reference. The study calculated mean absolute relative difference (MARD), an accuracy measure for CGM, for each device relative to the reference. Results showed comparable performance over the full 10-day wear period, with a MARD difference of 0.8%, the company said.
Sava said its proprietary CGM could offer a replacement for traditional, filament-based sensors inserted 5 mm to 10 mm into the skin with a hypodermic needle. Its miniaturized sensors reduce skin tissue disruption while maintaining access to interstitial fluid. Still, the company says its CGM maintains its accuracy and performance over the 10-day wear period.
The company believes the study, which showed accuracy drift by approximately 1.5% over the wear period, validates sustained accuracy, extended wear and real-world reliability.
Sava also hopes to build a modular, multi-analyte sensing platform that can detect additional molecules. The company plans to work toward a pivotal study this year in preparation for regulatory submissions, along with scaling manufacturing. It targets 2027 for commercial availability.
Commentary from Sava officials
Sava co-founder and co-CEO Renato Circi said:
“Microsensors were long treated as a ‘future promise’. Powerful in theory but unproven in practice. That phase is now over. We now know microsensing works, and the focus has shifted from possibility to scale.”
Sava co-founder and co-CEO Rafaël Michali said:
“Proving glucose was the first step. With that foundation in place, we can now expand into new analytes, unlocking entirely new applications built on the same technological foundation.”
